PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Anita M. Fremont, Esq., General Counsel, Penterra Pharmaceuticals Corp. Dr. Priya Nandakumar, VP, intellectual Property, Penterra Pharmaceuticals Corp.
FROM: Peter Vassiliev, Lead Associate, Calderwood & Harkness LLP Wendy Schultz, Working Associate, Calderwood & Harkness LLP
REVIEWED BY: Marcus Delgado, Partner, intellectual Property, Calderwood & Harkness LLP
DATE: September 8, 2023
RE: Comprehensive IP Due Diligence Report — PPC-4187 (Penteracitinib) Patent and Trademark Portfolio in Connection with Proposed Out-License to Meridian Bio Therapeutics Limited
MATTER NO.: 1018-00006
Right-click to update Table of Contents
I. Executive Summary
This memorandum sets forth the findings of the comprehensive intellectual property due diligence conducted by Calderwood & Harkness LLP ("C&H") in connection with Penterra Pharmaceuticals Corp.'s ("Penterra" or the "Company") proposed exclusive out-license of compound PPC-4187 (proposed International Nonproprietary Name: Penteracitinib) to Meridian Bio Therapeutics Limited ("Meridian") for the Asia-Pacific Territory (as defined below, the "Licensed Territory" or "Territory"). This report was prepared at the direction of Penterra's General Counsel, Anita M. Fremont, Esq., and is intended to inform the Company's decision-making regarding the execution and consummation of the proposed licensing transaction (the "Transaction").
Scope of Review. Our diligence encompassed a thorough review of all patent families, trademark registrations and applications, and licensed know-how relevant to the Licensed Territory, which comprises the following jurisdictions: the People's Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region), Japan, Republic of Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and Taiwan. We examined patent prosecution files maintained by Whitford & Cascade Insurance Brokers, patent office records in all Territory jurisdictions, trademark registry searches conducted in each Territory country, Penterra internal IP records provided by Dr. Priya Nandakumar, the Freedom-to-Operate opinion prepared by Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford), clinical data summaries related to Study PPC-4187-201, and Chemistry, Manufacturing, and Controls ("CMC") documentation from Alkerra Manufacturing Inc. ("Alkerra").
Key Conclusions. Based upon our comprehensive review, we conclude as follows:
• The PPC-4187 IP portfolio provides strong, enforceable protection across the Licensed Territory, with composition-of-matter patent protection extending through August 12, 2037 (before any patent term extension) in all major jurisdictions, including China, Japan, Republic of Korea, and Australia.
• Crystalline Form A patent protection extends through November 3, 2038, providing an additional layer of coverage.
• Trademark clearance for the proposed trade name PENTECLAR has been confirmed in all Territory countries, and no conflicting prior registrations or pending applications have been identified.
• The Freedom-to-Operate analysis conducted by Whitford & Marsh concludes that there is a low infringement risk associated with the manufacture, use, sale, and importation of PPC-4187 in the Licensed Territory.
• Certain limited third-party IP risks have been identified and are discussed in detail in Section VII below. These risks are assessed as low to moderate for specific Japanese method-of-use patents and low for all other Territory jurisdictions.
• The licensed know-how and data packages appear comprehensive and sufficient to support Phase III trial initiation and regulatory submissions across the Territory.
Diligence Period. Our diligence was conducted during the period from July 10, 2023 through September 8, 2023.
Materials Reviewed. The materials reviewed in connection with this report are itemized in detail in Appendix C and include: (i) patent prosecution files from Whitford & Cascade Insurance Brokers for all seven patent families, (ii) patent office records in all Territory jurisdictions accessed via official patent databases and through local counsel, (iii) trademark registry searches conducted in each Territory country, (iv) Penterra internal IP records provided by Dr. Priya Nandakumar, (v) the Whitford & Marsh FTO opinion dated August 22, 2023, (vi) clinical data summaries for Study PPC-4187-201, and (vii) CMC documentation from Alkerra Manufacturing Inc.
II. Background
A. The Compound — PPC-4187
PPC-4187 is a selective Janus kinase 1 ("JAK1") inhibitor under development by Penterra for the treatment of moderate-to-severe atopic dermatitis in adult patients. The compound has been designed as an oral, once-daily tablet formulation, offering a convenient dosing regimen intended to improve patient compliance relative to existing treatment modalities.
The proposed International Nonproprietary Name ("INN") for PPC-4187 is Penteracitinib, and the proposed commercial trade name is PENTECLAR. The compound is being developed in two dosage strengths — 25 mg and 50 mg film-coated tablets — both of which were evaluated in the completed Phase IIb clinical trial.
Penterra's internal development program for PPC-4187 has advanced through Phase IIb clinical development in the United States and European Union. The Company's pivotal Phase IIb study, designated Study PPC-4187-201, enrolled 420 patients with moderate-to-severe atopic dermatitis and evaluated the efficacy and safety of PPC-4187 at 25 mg and 50 mg daily doses compared to placebo. Topline results from Study PPC-4187-201, announced in June 2023, demonstrated statistically significant improvement versus placebo, with the primary endpoint of EASI-75 response at Week 16 achieving a p-value of less than 0.001 (p<0.001) for both dose levels. These results represent a clinically meaningful efficacy signal that supports advancement into Phase III clinical development.
From a Chemistry, Manufacturing, and Controls perspective, the manufacturing process for PPC-4187 has been fully validated at Alkerra Manufacturing Inc., located at 5200 Meridian Parkway, Research Triangle Park, North Carolina 27713. Alkerra serves as Penterra's contract manufacturing organization ("CMO") for the production of PPC-4187 drug product. All intellectual property generated by Alkerra in the course of its manufacturing activities is owned by Penterra pursuant to the terms of the Master Services Agreement between the parties, as discussed further in Section VIII.C below.
B. The Proposed Transaction
Pursuant to the proposed Transaction, Penterra will grant Meridian an exclusive license to develop, manufacture, and commercialize PPC-4187 (Penteracitinib) in the Asia-Pacific Territory defined below. The Transaction is structured as an out-license arrangement in which Meridian assumes responsibility for all regulatory, clinical development, and commercialization activities within the Territory, while Penterra retains all rights to PPC-4187 outside the Territory.
The total deal value of the Transaction is up to $120,000,000, structured as follows:
• Upfront Payment: $18,000,000, payable at closing;
• Development Milestones: $32,000,000, payable upon achievement of specified clinical development milestones, including initiation of Phase III trials, completion of pivotal studies, and submission of regulatory applications in key Territory jurisdictions;
• Regulatory Milestones: $25,000,000, payable upon receipt of regulatory approvals from the NMPA (China), PMDA (Japan), MFDS (South Korea), TGA (Australia), and designated ASEAN regulatory agencies;
• Commercial Milestones: $45,000,000, payable upon achievement of specified annual net sales thresholds in the Territory.
In addition, Penterra will receive tiered royalties on net sales of PPC-4187 in the Territory at rates of 8% on net sales up to $200,000,000, 11% on net sales between $200,000,000 and $500,000,000, and 14% on net sales in excess of $500,000,000.
Penterra retains all rights to PPC-4187 outside the Licensed Territory, including the United States, Canada, the European Union / European Economic Area, the United Kingdom, Latin America, the Middle East, Africa, and all other countries and territories not expressly included in the Licensed Territory.
C. The Licensed Territory
The Licensed Territory encompasses the following jurisdictions:
1. People's Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region)
2. Japan
3. Republic of Korea
4. Australia
5. New Zealand
6. Singapore
7. Thailand
8. Malaysia
9. Indonesia
10. Philippines
11. Vietnam
12. Taiwan
Meridian's regional presence in the Territory is supported by several subsidiaries: Meridian Pharma (Shanghai) Co., Ltd., a PRC wholly foreign-owned enterprise ("WFOE") established to conduct regulatory and commercial operations in mainland China; Meridian Japan K.K., headquartered in Tokyo, which will serve as the Japanese development and commercialization entity; Meridian Korea Inc., based in Seoul, responsible for South Korean operations; and Meridian Bio Australia Pty Ltd, headquartered in Sydney, which will oversee Australian and New Zealand activities.
Meridian has an established commercialization footprint in the Territory, with existing regulatory approvals and commercial infrastructure for other products in China (through the National Medical Products Administration, "NMPA"), Japan (through the Pharmaceuticals and Medical Devices Agency, "PMDA"), South Korea (through the Ministry of Food and Drug Safety, "MFDS"), Australia (through the Therapeutic Goods Administration, "TGA"), and six additional ASEAN markets. This existing infrastructure is expected to facilitate the efficient development and commercialization of PPC-4187 in the Territory.
III. Patent Portfolio Overview
A. Summary of Patent Families
Penterra's PPC-4187 patent portfolio comprises seven (7) patent families, each directed to a distinct aspect of the compound's intellectual property:
These seven patent families collectively provide a layered intellectual property strategy designed to protect PPC-4187 from multiple angles — the compound itself (Family 1), its preferred crystalline form (Family 2), its therapeutic application (Family 3), its pharmaceutical formulation (Family 4), its manufacturing methodology (Family 5), its use in combination treatment regimens (Family 6), and additional polymorphic forms of the active pharmaceutical ingredient (Family 7). This multi-layered approach provides both foundational protection through the composition-of-matter patents and extended lifecycle management through the formulation, process, and polymorph patents.
All patent prosecution for the PPC-4187 portfolio has been handled by Whitford & Cascade Insurance Brokers, under the direction of Dr. Alan J. Whitford, located at 1750 K Street NW, Suite 600, Washington, DC 20006. Whitford & Marsh serves as Penterra's primary patent prosecution counsel and has managed both U.S. and international filing strategies for the PPC-4187 portfolio since the initial provisional application filings.
B. Patent Family Details — Jurisdiction-by-Jurisdiction Analysis
Family 1: Composition of Matter
Family 1 is the cornerstone of Penterra's PPC-4187 patent portfolio. The claims in this family are directed to the PPC-4187 compound itself — its chemical structure — and pharmaceutically acceptable salts thereof. Composition-of-matter patents are generally considered the strongest form of patent protection for pharmaceutical compounds because they cover the active ingredient regardless of formulation, dosage form, indication, or manufacturing process.
United States. U.S. Patent No. 11,234,567 was granted by the United States Patent and Trademark Office ("USPTO") and is currently in force. The patent expires on August 12, 2037, prior to any patent term extension that may be available under 35 U.S.C. § 156 following FDA approval. The independent claims are directed to the PPC-4187 compound (defined by chemical structure) and pharmaceutically acceptable salts thereof, including the hydrochloride salt and the mesylate salt. Dependent claims recite specific salt forms, pharmaceutical compositions comprising the compound, and methods of administering the compound. While the U.S. patent is not directly within the Licensed Territory, it serves as the foundational patent in the global family and its prosecution history is relevant to the analysis of related Territory patents.
China (People's Republic of China). CN Patent No. ZL 2020 1 0456789.0 was granted by the China National intellectual Property Administration ("CNIPA") and is currently in force. The patent expires on August 12, 2037. This patent was filed as a national phase entry from PCT Application No. PCT/US2019/045123, with the national phase entry in China made on February 11, 2021, within the applicable 30-month deadline under the Patent Cooperation Treaty. The claims of the Chinese patent are directed to the PPC-4187 compound and pharmaceutically acceptable salts thereof, with claim scope that is substantially aligned with the U.S. composition-of-matter claims, subject to certain minor adjustments made during examination to conform with CNIPA examination guidelines. Specifically, the Chinese claims include a Markush structure definition of the compound rather than the IUPAC nomenclature format used in certain U.S. claims, though both definitions encompass the same chemical entity. No invalidation requests have been filed against this patent.
Japan. JP Patent No. 7,012,345 was granted by the Japan Patent Office ("JPO") and is currently in force, with an expiration date of August 12, 2037. This patent was likewise filed as a national phase entry from PCT/US2019/045123, with national phase entry in Japan made on February 8, 2021. The claims are directed to the PPC-4187 compound and pharmaceutically acceptable salts thereof, consistent with the global family. No opposition was filed during the six-month post-grant opposition period, which has now expired. The patent is eligible for patent term extension under Japanese Patent Law Article 67(2) upon receipt of PMDA marketing approval for Penteracitinib, which could extend the effective patent life by up to five years depending on the length of the regulatory review period.
Republic of Korea. KR Patent No. 10-2345678 was granted by the Korean intellectual Property Office ("KIPO") and is currently in force, expiring on August 12, 2037. The patent was filed as a national phase entry from PCT/US2019/045123, with national phase entry made on February 10, 2021. The claim scope is consistent with the composition-of-matter claims in other jurisdictions. No invalidation trials have been initiated before the intellectual Property Trial and Appeal Board of KIPO. Upon receipt of MFDS marketing approval, this patent will be eligible for listing on the Korean patent linkage system, providing an additional layer of protection against generic entry.
Australia. AU Patent No. 2020234567 was granted by IP Australia and is currently in force, with an expiration date of August 12, 2037 (before any extension). The patent was filed as a national phase entry from PCT/US2019/045123, with national phase entry made on February 12, 2021. The examination history is clean, with no re-examination or opposition proceedings. Under Australian patent law, a patent term extension of up to five (5) years is available for pharmaceutical substance patents upon receipt of TGA approval, pursuant to Section 70 of the Patents Act 1990 (Cth). If obtained, this extension could extend the effective composition-of-matter patent life in Australia to as late as August 12, 2042, subject to the statutory requirements and timing of TGA approval.
Singapore. Application No. SG 11202101234A is currently pending before the intellectual Property Office of Singapore ("IPOS"). The application was filed as a national phase entry from PCT/US2019/045123 on February 11, 2021. Claims are directed to the PPC-4187 compound and pharmaceutically acceptable salts thereof. The examination report has been issued, and Whitford & Cascade Insurance Brokers is preparing a response to certain formal objections. No substantive prior art rejections have been raised. Grant is expected by Q1 2024, and the patent, if granted, will expire on August 12, 2037.
Thailand. Application No. TH 2102001234 is currently pending before the Department of intellectual Property, Ministry of Commerce, Thailand. The application was filed as a national phase entry from PCT/US2019/045123 on February 12, 2021. Thailand's patent examination process is notably slower than other jurisdictions in the Territory, and a substantive examination has not yet commenced. Based on typical prosecution timelines, grant is expected by 2025–2026. The patent, if granted, will expire on August 12, 2037.
Malaysia. Application No. PI 2021001234 is currently pending before the intellectual Property Corporation of Malaysia ("MyIPO"). National phase entry was made on February 11, 2021. A request for substantive examination was filed, and the application is awaiting a first office action. Grant is expected by Q2–Q3 2024, and the patent, if granted, will expire on August 12, 2037.
Indonesia. Application No. IDP000078901 is currently pending before the Directorate General of intellectual Property ("DGIP"), Ministry of Law and Human Rights, Indonesia. National phase entry was made on February 12, 2021. Indonesia's examination process for pharmaceutical patents has historically been lengthy, and grant is expected by 2025–2026. The patent, if granted, will expire on August 12, 2037. We note that Indonesia has specific requirements regarding the patentability of pharmaceutical compounds, and Whitford & Cascade Insurance Brokers has confirmed that the claims as drafted are consistent with Indonesian Patent Law No. 13 of 2016.
Philippines. Application No. PH 1/2021/050234 is currently pending before the intellectual Property Office of the Philippines ("IPOPHL"). National phase entry was made on February 10, 2021. The application is undergoing substantive examination, and a first office action was received in May 2023 raising a formal objection regarding the description of the invention; no prior art rejections were raised. A response was filed in July 2023 by local counsel. Grant is expected by Q1–Q2 2024, and the patent, if granted, will expire on August 12, 2037.
Vietnam. Application No. VN 1-2021-01234 is currently pending before the National Office of intellectual Property of Vietnam ("NOIP"). National phase entry was made on February 11, 2021. Vietnam's patent examination system relies heavily on examination results from other patent offices (particularly the USPTO, JPO, and EPO), and the grant of the corresponding U.S. and Japanese patents is expected to facilitate prosecution. Grant is expected by 2024–2025, and the patent, if granted, will expire on August 12, 2037.
Taiwan. Application No. TW 110104567 is currently pending before the Taiwan intellectual Property Office ("TIPO"). National phase entry was made on February 9, 2021. We note that Taiwan is not a member of the Patent Cooperation Treaty, and the application was filed directly as a Taiwan national application claiming priority from the PCT application. A first office action was received in March 2023 with minor claim amendments requested; a response was filed in June 2023. Grant is expected by Q4 2023–Q1 2024, and the patent, if granted, will expire on August 12, 2037.
New Zealand. Application No. NZ 780123 is currently pending before the intellectual Property Office of New Zealand ("IPONZ"). National phase entry was made on February 12, 2021. New Zealand follows a modified examination system, and examination is proceeding without substantive objections. Grant is expected by Q4 2023, and the patent, if granted, will expire on August 12, 2037.
Family 2: Crystalline Form A
Family 2 is directed to Crystalline Form A of PPC-4187, which is the preferred crystalline form of the active pharmaceutical ingredient used in the commercial formulation. The claims cover the crystalline form characterized by specific X-ray powder diffraction ("XRPD") peaks, differential scanning calorimetry ("DSC") endotherm data, and thermogravimetric analysis ("TGA") profiles, as well as processes for the preparation of Crystalline Form A.
United States. U.S. Patent No. 11,345,678 was granted by the USPTO and is currently in force. The patent expires on November 3, 2038, providing approximately fifteen months of additional patent protection beyond the composition-of-matter patent. The independent claims are directed to the crystalline form of PPC-4187 characterized by specific XRPD peaks at 2θ values of 7.2°, 14.8°, 18.3°, 21.6°, and 24.9° (±0.2°), and dependent claims recite processes for preparing the crystalline form and pharmaceutical compositions comprising the crystalline form.
China (PRC). Application No. CN 202110567890.1 was filed on March 15, 2021 and is currently pending examination before CNIPA. The claims are directed to Crystalline Form A of PPC-4187, consistent with the U.S. patent. A first office action was received in April 2023, raising an objection regarding the characterization of the crystalline form; a response was filed in August 2023 by Whitford & Cascade Insurance Brokers's Chinese associate counsel. Grant is expected by Q1–Q2 2024, and the patent, if granted, will expire on November 3, 2038.
Japan. JP Application No. 2021-045678 was filed on March 12, 2021 and is currently pending before the JPO. No office actions have been received to date. Based on JPO examination timelines for pharmaceutical patents, grant is expected by Q2 2024, and the patent, if granted, will expire on November 3, 2038.
Republic of Korea. KR Application No. 10-2021-0034567 was filed on March 14, 2021 and is currently pending before KIPO. A first office action was received in June 2023, and a response is being prepared. No prior art rejections have been raised; the objections relate to claim formatting requirements under Korean practice. Grant is expected by Q1 2024, and the patent, if granted, will expire on November 3, 2038.
Australia. AU Application No. 2021201890 was filed on March 16, 2021 and is currently pending before IP Australia. Examination has been requested, and the application is awaiting a first examination report. Based on IP Australia's standard timelines, grant is expected by Q1–Q2 2024, and the patent, if granted, will expire on November 3, 2038.
Other Territory Jurisdictions (SG, TH, MY, ID, PH, VN, TW, NZ). National phase entries or direct national filings for Family 2 have been made in Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, Taiwan, and New Zealand. All applications are currently pending at various stages of prosecution. Expected grant timelines range from Q1 2024 (Singapore, New Zealand) to 2025–2026 (Thailand, Indonesia). In all cases, the patent, if granted, will expire on November 3, 2038.
Families 3 through 7
Family 3 — Methods of Use (Atopic Dermatitis). This family covers methods of treating moderate-to-severe atopic dermatitis in adult patients by administering PPC-4187 at therapeutically effective doses. Claims are directed to specific dosing regimens (25 mg and 50 mg once daily), treatment durations, and patient populations. The PCT application (PCT/US2019/045123) serves as the parent for national phase entries. U.S. Patent No. 11,456,789 was granted on April 18, 2023, with an expiration date of August 12, 2037. National phase applications have been filed in all Territory jurisdictions and are at various stages of prosecution. Grants have been obtained in Japan (JP Patent No. 7,023,456, granted March 7, 2023) and Australia (AU Patent No. 2020245678, granted January 19, 2023). Applications remain pending in China, South Korea, Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, Taiwan, and New Zealand.
Family 4 — Formulation (Film-Coated Tablet). This family is directed to the pharmaceutical formulation of PPC-4187 as a film-coated tablet, including specific excipient compositions, film-coating materials, and dissolution profiles. The PCT application underlying this family is PCT/US2020/012345, filed on January 6, 2020, with a priority date of January 7, 2019. U.S. Patent No. 11,567,890 was granted on June 13, 2023, with an expiration date of January 6, 2040. National phase entries have been made in all Territory jurisdictions, and all applications are currently pending. The extended expiration date of this family — nearly three years beyond the composition-of-matter patent — provides valuable lifecycle management protection for the commercial formulation.
Family 5 — Manufacturing Process. This family covers the synthetic process for manufacturing PPC-4187, including key intermediates, reaction conditions, purification steps, and the final crystallization process. Claims are designed to protect Penterra's proprietary manufacturing methodology developed in collaboration with Alkerra Manufacturing Inc. The PCT application underlying this family is PCT/US2020/012346, filed on January 6, 2020. U.S. Patent No. 11,678,901 was granted on July 25, 2023, with an expiration date of January 6, 2040. National phase entries have been made in the major Territory jurisdictions (China, Japan, South Korea, Australia) and are pending. We note that process patents provide more limited protection than composition-of-matter patents because they cover only the specific manufacturing route claimed and can potentially be designed around by competitors employing alternative synthetic pathways.
Family 6 — Combination Therapies. This family covers the use of PPC-4187 in combination with other therapeutic agents for the treatment of inflammatory and autoimmune conditions, including atopic dermatitis. Specifically, claims are directed to combinations of PPC-4187 with topical corticosteroids, calcineurin inhibitors, and biologic agents. The PCT application underlying this family is PCT/US2021/023456, filed on March 22, 2021, with a priority date of March 23, 2020. U.S. Application No. 17/456,789 is currently pending. National phase entries have been made in China, Japan, South Korea, Australia, and selected ASEAN jurisdictions. All applications are currently pending, and examination has not yet commenced in most jurisdictions. If granted, patents in this family will expire on March 22, 2041.
Family 7 — Polymorphic Forms. This family covers additional polymorphic forms of PPC-4187 beyond Crystalline Form A (covered by Family 2), including Forms B, C, and D, as well as an amorphous form. The purpose of this family is to provide defensive patent protection against competitors who might seek to develop alternative solid-state forms of the compound. The PCT application underlying this family is PCT/US2021/023457, filed on March 22, 2021, with a priority date of March 24, 2020. U.S. Application No. 17/456,790 is currently pending. National phase entries have been made in China, Japan, South Korea, and Australia, and all applications are pending. If granted, patents in this family will expire on March 22, 2041.
C. Patent Family Summary Table
The following table provides a consolidated summary of all seven patent families in the PPC-4187 portfolio. Detailed information for each jurisdiction is set forth in Appendix A.
IV. Patent Validity and Enforceability Analysis
A. Methodology
Our patent validity and enforceability analysis was conducted through a multi-faceted review process encompassing the following elements:
1. Prosecution History Review. We reviewed the complete prosecution histories (file wrappers) for all granted patents in the PPC-4187 portfolio, including examiner actions, applicant responses, claim amendments, declarations, and notices of allowance. For pending applications, we reviewed all prosecution correspondence to date.
2. Prior Art Analysis. We analyzed all prior art references cited during prosecution — both by patent examiners and by the applicant through Information Disclosure Statements — to assess whether any cited references, individually or in combination, could support a potential invalidity challenge based on anticipation (35 U.S.C. § 102 or foreign equivalents) or obviousness (35 U.S.C. § 103 or foreign equivalents).
3. Invalidity Challenge Assessment. We evaluated the vulnerability of each granted patent to potential invalidity challenges on the grounds of anticipation, obviousness, lack of enablement, insufficient written description, and indefiniteness. This assessment was informed by the prosecution histories, the cited prior art landscape, and relevant case law in each jurisdiction.
4. Post-Grant Proceedings Review. We searched for and reviewed any post-grant proceedings, including inter partes review ("IPR") petitions in the United States, invalidation requests before CNIPA in China, oppositions before the JPO in Japan, invalidation trials before KIPO in South Korea, and re-examination or opposition proceedings before IP Australia. No such proceedings were identified for any patent in the PPC-4187 portfolio.
B. United States
U.S. Patent No. 11,234,567 (Composition of Matter). Our review of the prosecution history for the composition-of-matter patent revealed a clean and straightforward prosecution. The original application was filed on August 12, 2019, as a national phase entry from PCT/US2019/045123. During prosecution, the examiner issued a single non-final office action citing three prior art references: (i) Tanaka et al., J. Med. Chem. 2016, 59(3), 1370–1381 (disclosing JAK inhibitor scaffolds with a different core structure); (ii) U.S. Patent No. 9,567,890 (assigned to a third party, claiming a structurally distinct JAK1/JAK2 inhibitor); and (iii) WO 2017/045678 (a PCT publication disclosing a genus of kinase inhibitors). In response, Whitford & Cascade Insurance Brokers submitted a detailed declaration by Dr. Susan Patel, Penterra's Director of Medicinal Chemistry, establishing the structural distinctions between PPC-4187 and the cited references, as well as the unexpected selectivity profile of PPC-4187 for JAK1 over JAK2 and JAK3. The examiner found the response persuasive and issued a notice of allowance without requiring claim amendments. No prior art rejections were therefore maintained, and the claims issued as originally filed with only minor formal corrections.
No inter partes review ("IPR") petitions have been filed against U.S. Patent No. 11,234,567 before the Patent Trial and Appeal Board ("PTAB"). No requests for ex parte reexamination have been filed. The patent has not been the subject of any litigation challenging its validity.
U.S. Patent No. 11,345,678 (Crystalline Form A). The prosecution history for the Crystalline Form A patent is similarly clean. The examiner issued a restriction requirement between the crystalline form claims and the process-of-preparation claims, which was traversed but ultimately complied with; the process claims were pursued in a divisional application (which became U.S. Patent No. 11,678,901 in Family 5). The crystalline form claims proceeded to examination and were allowed after a single office action in which the examiner raised a non-statutory double-patenting rejection over U.S. Patent No. 11,234,567. Whitford & Cascade Insurance Brokers argued that the crystalline form claims were patentably distinct from the composition-of-matter claims because they required specific XRPD characterization data and were directed to a specific solid-state form, not merely the compound in generic form. The examiner accepted this argument and withdrew the rejection. Notably, no terminal disclaimer was filed to overcome the double-patenting rejection, meaning that the Crystalline Form A patent is not subject to any terminal disclaimer linking it to the composition-of-matter patent. This is significant because it means the Crystalline Form A patent can be independently enforced and is not subject to co-termination with the composition-of-matter patent.
No IPR petitions or reexamination requests have been filed against U.S. Patent No. 11,345,678.
Assessment. Both U.S. patents are considered valid and enforceable based on our review. The prosecution histories are clean, no prior art references that would materially undermine validity have been identified, and no post-grant challenges have been initiated. We have not identified any material prosecution history estoppel issues that would limit the scope of the claims in enforcement proceedings. The absence of terminal disclaimers between the two patents is a favorable factor for portfolio strength.
C. China (PRC)
CN Patent No. ZL 2020 1 0456789.0 (Composition of Matter). The Chinese composition-of-matter patent was granted by CNIPA following a standard examination process. During examination, the CNIPA examiner issued two office actions. The first office action raised a novelty objection based on a Chinese patent application publication (CN 108234567 A) that disclosed a genus of JAK inhibitors. Whitford & Cascade Insurance Brokers's Chinese associate counsel responded by distinguishing PPC-4187's specific chemical structure from the generic Markush genus disclosed in the cited reference and providing evidence of PPC-4187's unexpected therapeutic efficacy. The second office action raised an inventive step (obviousness equivalent) objection combining the same reference with a journal article published in the Chinese Journal of Medicinal Chemistry (2017). The response included a declaration from Dr. Patel regarding the unpredictable structure-activity relationships in the JAK inhibitor class, which the examiner found persuasive. The patent was subsequently granted with claims substantially aligned with the U.S. composition-of-matter claims.
No invalidation requests have been filed against this patent before the Patent Reexamination and Invalidation Department of CNIPA. We note that under PRC Patent Law, any person may file an invalidation request at any time after grant, and this risk should be monitored on an ongoing basis, particularly as PPC-4187 approaches commercialization in the Chinese market.
Regarding enforceability, the PRC patent provides strong legal protection. The PRC Patent Law was most recently amended in 2020 (effective June 1, 2021), with amendments that strengthened patent protection for pharmaceutical products, including the introduction of a patent linkage system, early resolution mechanisms, and provisions for patent term compensation. We note that patent term compensation (the PRC equivalent of patent term extension) is available for new drug patents under Article 42(3) of the PRC Patent Law, which could potentially extend the effective term of CN Patent No. ZL 2020 1 0456789.0 beyond August 12, 2037, for up to five years (with a total effective patent life not exceeding 14 years from the date of drug marketing approval). Eligibility for patent term compensation will depend on the timing of NMPA approval for Penteracitinib.
D. Japan
JP Patent No. 7,012,345 (Composition of Matter). The Japanese composition-of-matter patent was granted by the JPO following a relatively straightforward examination. The examiner issued a single office action raising a lack-of-inventive-step rejection under Section 29(2) of the Japanese Patent Act, based on a combination of two prior art references — a published PCT application (WO 2016/087654) disclosing a related JAK inhibitor scaffold and a Bioorganic & Medicinal Chemistry Letters article (2017) disclosing JAK1 selectivity data for a structurally distinct compound. Whitford & Cascade Insurance Brokers's Japanese associate counsel submitted a response with claim amendments narrowing the genus of pharmaceutically acceptable salts to specific named salts and providing an experimental comparison demonstrating the superior JAK1 selectivity of PPC-4187 relative to the compounds disclosed in the cited prior art. The examiner issued a notice of allowance following the response.
The six-month post-grant opposition period under Japanese Patent Law Article 113 has expired without any opposition being filed. This is a favorable factor because post-grant opposition is the primary mechanism for challenging patent validity at the JPO, and the absence of any opposition filing provides increased confidence in the patent's stability.
Regarding patent term extension, Japanese Patent Law Article 67(2) permits extension of the patent term for pharmaceutical patents by up to five (5) years based on the period of regulatory review required to obtain marketing approval from the PMDA. Given that Meridian is expected to initiate Phase III clinical development in Japan, the timing of PMDA approval will determine the available extension period. If PMDA approval is obtained in, for example, 2030, and the regulatory review period is determined to be approximately three years, the effective patent life could be extended to approximately August 12, 2040. The precise calculation will depend on the actual regulatory timeline and the application of the statutory formula.
E. Republic of Korea
KR Patent No. 10-2345678 (Composition of Matter). The Korean composition-of-matter patent was granted by KIPO following a two-action prosecution. The first office action raised a novelty rejection based on a Korean patent application publication (KR 10-2018-0045678 A) disclosing a structurally related compound. The response distinguished PPC-4187 on structural and pharmacological grounds, and the examiner subsequently allowed the claims. The second office action addressed only formal matters regarding claim formatting and was resolved without difficulty.
No invalidation trials have been initiated before KIPO's intellectual Property Trial and Appeal Board ("IPTAB") with respect to this patent. We note that under Korean Patent Law, any interested party may file an invalidation trial request, and this avenue remains available to potential challengers. However, based on our review of the prosecution history and prior art landscape, we do not consider this patent to be materially vulnerable to invalidity challenge.
Regarding the Korean patent linkage system, we note that South Korea implemented a patent linkage system effective March 15, 2015, pursuant to which approved pharmaceutical patents may be listed in the Green List maintained by the MFDS. Upon receipt of MFDS marketing approval for Penteracitinib, KR Patent No. 10-2345678 should be listed on the Green List to trigger the automatic stay provisions that provide protection against generic drug applications. Meridian Korea Inc. should coordinate with Penterra's IP counsel to ensure timely listing.
F. Australia
AU Patent No. 2020234567 (Composition of Matter). The Australian composition-of-matter patent was granted by IP Australia following a clean examination process. Only one examination report was issued, and it raised minor objections relating to the format of the claims and the sufficiency of the description of certain salt forms. Whitford & Cascade Insurance Brokers's Australian associate counsel filed an amended claim set and a responsive submission, and the patent was subsequently accepted and granted. No re-examination proceedings have been initiated, and no opposition was filed during the three-month post-acceptance opposition period.
Regarding patent term extension, Section 70 of the Patents Act 1990 (Cth) provides for an extension of the term of a standard patent relating to a pharmaceutical substance by up to five (5) years. The extension is calculated based on the period between the date of the patent (i.e., the filing date) and the date of first regulatory inclusion on the Australian Register of Therapeutic Goods ("ARTG") following TGA approval, reduced by five years. Assuming a TGA approval date of approximately 2029, the extension could add up to five years to the patent term, potentially extending protection to August 12, 2042. Meridian Bio Australia Pty Ltd should be advised to coordinate with Penterra's patent counsel regarding the timing and filing of the patent term extension application upon receipt of TGA approval.
G. Pending Applications (Singapore, ASEAN, Taiwan, New Zealand)
As detailed in Section III.B above, national phase applications for the composition-of-matter family (Family 1) are currently pending in Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, Taiwan, and New Zealand. Our assessment of the likelihood of grant in each of these jurisdictions is as follows:
Singapore. High likelihood of grant. The IPOS examination system relies heavily on search and examination results from corresponding applications in recognized patent offices (including the USPTO, EPO, JPO, and KIPO). The grant of the U.S. and Japanese patents strongly supports the patentability of the corresponding Singapore application. Grant is expected by Q1 2024.
Thailand. Moderate to high likelihood of grant. Thai patent examination timelines are significantly longer than other jurisdictions, and prosecution may extend into 2025–2026. However, the substantive patentability criteria are expected to be met based on the prosecution outcomes in other jurisdictions.
Malaysia. High likelihood of grant. MyIPO's examination process for pharmaceutical patents is generally predictable, and the prosecution outcomes in the U.S. and Japan will be persuasive. Grant is expected by Q2–Q3 2024.
Indonesia. Moderate likelihood of grant. Indonesia has historically been more restrictive in granting pharmaceutical patents, and certain claim scope adjustments may be required during prosecution. However, the composition-of-matter claims directed to a novel chemical entity are expected to satisfy Indonesian patentability requirements. Grant is expected by 2025–2026.
Philippines. High likelihood of grant. IPOPHL's examination process is proceeding without substantive prior art objections. Grant is expected by Q1–Q2 2024.
Vietnam. Moderate to high likelihood of grant. NOIP relies on examination results from other patent offices, and the grants in the U.S. and Japan are expected to facilitate prosecution. Grant is expected by 2024–2025.
Taiwan. High likelihood of grant. TIPO is well-resourced and the application is in advanced prosecution. Grant is expected by Q4 2023–Q1 2024.
New Zealand. High likelihood of grant. IPONZ examination is proceeding without substantive objections. Grant is expected by Q4 2023.
We have not identified any jurisdiction in which material claim narrowing is likely to be required. The composition-of-matter claims, which are directed to a novel chemical entity, are expected to be grantable in all Territory jurisdictions without significant limitations.
H. Overall Validity Assessment
Based on our comprehensive review, we conclude that the PPC-4187 patent portfolio occupies a strong validity position across all Territory jurisdictions. The key bases for this conclusion are as follows:
• Clean prosecution histories in all jurisdictions where patents have been granted, with all prior art rejections satisfactorily overcome through persuasive arguments and, where necessary, narrow claim amendments that do not materially limit the scope of protection.
• No identified prior art that would pose a material invalidity risk. The prior art cited during prosecution does not anticipate PPC-4187's specific chemical structure, and the combinations of references cited in obviousness-type rejections were successfully distinguished on structural and pharmacological grounds.
• No post-grant challenges filed in any jurisdiction, including no IPR petitions in the U.S., no invalidation requests in China, no oppositions in Japan, no invalidation trials in Korea, and no re-examinations or oppositions in Australia.
• Consistent claim scope across jurisdictions, providing a unified and Penrose & Co. patent strategy.
V. Freedom-to-Operate Analysis
A. Summary of Whitford & Marsh FTO Opinion
Dr. Alan J. Whitford of Whitford & Cascade Insurance Brokers prepared a comprehensive Freedom-to-Operate ("FTO") opinion, dated August 22, 2023, analyzing the risks associated with the manufacture, use, sale, offer for sale, and importation of PPC-4187 (Penteracitinib) in the Licensed Territory. The FTO opinion was prepared at Penterra's direction and is subject to the protections of the attorney-client privilege and attorney work product doctrine. The analysis was conducted across all Territory jurisdictions and covered the 25 mg and 50 mg film-coated tablet formulations of PPC-4187 for the treatment of moderate-to-severe atopic dermatitis in adult patients.
Calderwood & Harkness has reviewed the Whitford & Marsh FTO opinion for purposes of this due diligence report. We have not independently verified the third-party patent claims analyzed in the FTO opinion but have relied upon Whitford & Marsh's analysis and conclusions, which we consider reasonable and well-supported based on our own familiarity with the JAK inhibitor patent landscape.
B. Third-Party Patent Landscape
The FTO analysis identified a total of forty-seven (47) third-party patent families in the JAK inhibitor space with claims potentially relevant to the Licensed Territory. These patent families are owned by or assigned to various pharmaceutical companies and academic institutions, including Northpoint Holdings (tofacitinib-related patents), Cobalt Ridge Group (upadacitinib-related patents), Cascade Corporation (baricitinib-related patents), Granite Harbor Enterprises (ruxolitinib-related patents), and Crowne Albany Partners LLC (various JAK inhibitor patents in Japan).
The analysis examined the claim scope of each identified third-party patent relative to three dimensions of PPC-4187's intellectual property: (i) the chemical structure of PPC-4187 (composition-of-matter claims), (ii) the pharmaceutical formulation (formulation claims), and (iii) the manufacturing process (process claims). Additionally, method-of-use claims directed to the treatment of atopic dermatitis or related dermatological conditions using JAK inhibitors were analyzed.
Country-by-Country Assessment:
• China (PRC): Twenty-three (23) third-party patent families with granted or pending claims in China were analyzed. None of the identified composition-of-matter claims encompass PPC-4187's specific chemical structure. Two method-of-use patents were identified (CN ZL 2017 1 0345678.X and CN ZL 2018 1 0567890.3) with claims directed to JAK inhibitors for dermatological conditions, but these claims are limited to structurally specific compounds that are chemically distinct from PPC-4187. One pending application (CN 202010890123.4) was flagged for monitoring due to the breadth of its Markush claims during prosecution.
• Japan: Eighteen (18) third-party patent families were analyzed. The Japanese patent landscape for JAK inhibitors is particularly dense given the significant presence of Japanese pharmaceutical companies in this therapeutic area. Three method-of-use patents were identified as potentially relevant: JP Patent No. 6,789,012 (Crowne Albany Partners LLC), JP Patent No. 6,890,123 (Cascade Group), and JP Patent No. 6,901,234 (Pemberton Group). These patents contain claims directed to methods of treating dermatological conditions with JAK inhibitors, with varying degrees of structural limitation in the claim language. The analysis of these patents is discussed further in Section V.C below.
• Republic of Korea: Fourteen (14) third-party patent families were analyzed. No composition-of-matter overlap was identified. Method-of-use claims in the Korean patents were found to be limited to specific compounds and did not encompass PPC-4187.
• Australia: Twelve (12) third-party patent families were analyzed. No material infringement risk was identified. Australian claims generally mirror the corresponding U.S. or European claims and do not present unique freedom-to-operate concerns.
• ASEAN Jurisdictions: A limited number of third-party JAK inhibitor patents have been granted in ASEAN countries. The patent landscape in these jurisdictions is less developed than in China, Japan, and Korea, and the FTO risk is assessed as low.
C. FTO Conclusions
The overall conclusion of the Whitford & Marsh FTO opinion, with which we concur, is that there is a low infringement risk associated with the manufacture, use, sale, and importation of PPC-4187 across all Territory jurisdictions.
The key bases for this conclusion are as follows:
1. No composition-of-matter overlap. PPC-4187's novel chemical structure is not encompassed by any identified third-party composition-of-matter patent claim in any Territory jurisdiction. The selective JAK1 mechanism and the distinctive chemical scaffold of PPC-4187 differentiate it from the compounds claimed in existing JAK inhibitor patents, which are directed to structurally distinct molecules (e.g., tofacitinib, upadacitinib, baricitinib, ruxolitinib, and their analogs).
2. Formulation and manufacturing process claims. The 25 mg and 50 mg film-coated tablet formulation of PPC-4187 does not infringe any identified third-party formulation claims. The excipient compositions, film-coating specifications, and dissolution profiles of PPC-4187 tablets are distinct from those claimed in third-party formulation patents. Similarly, Penterra's proprietary manufacturing process does not overlap with any identified third-party process claims.
3. Method-of-use patents — Japan. Three Japanese method-of-use patents were identified as potentially relevant: JP Patent Nos. 6,789,012; 6,890,123; and 6,901,234. Upon detailed claim construction analysis, Dr. Whitford concluded that these patents are distinguishable from PPC-4187 on the following grounds:
• JP Patent No. 6,789,012 (Astellas): Claims are limited to methods of treating dermatological conditions using a compound having a specific structural feature (a pyrrolo[2,3-d]pyrimidine core) that is absent from PPC-4187's chemical structure.
• JP Patent No. 6,890,123 (Daiichi Sankyo): Claims require coadministration of the JAK inhibitor with a specific topical corticosteroid at defined dosing intervals, which differs from PPC-4187's monotherapy treatment regimen.
• JP Patent No. 6,901,234 (Ono): Claims are limited to methods of treating a specific subpopulation of atopic dermatitis patients defined by biomarker criteria that are not part of PPC-4187's intended label.
While these method-of-use patents do not present a high infringement risk, they warrant ongoing monitoring given the possibility that claim scope could be interpreted more broadly in Japanese court proceedings than our current analysis suggests. The risk level for these Japanese method-of-use patents is assessed as low to moderate.
D. Recommendations
Based on the FTO analysis, we recommend the following:
1. Ongoing Monitoring. Penterra and Meridian should implement a systematic patent watch service to monitor new third-party patent filings in all Territory jurisdictions, with particular emphasis on Japan and China, where the JAK inhibitor patent landscape is most active.
2. Design-Around Strategies. If any pending third-party applications in the Territory (particularly CN Application No. 202010890123.4) issue with claims broader than currently anticipated, Penterra and Meridian should consider formulation design-around strategies to further mitigate risk.
3. Indemnification Protections. Penterra's indemnification obligation under the proposed License Agreement covers pre-existing IP infringement claims arising from the Licensed IP as of the Effective Date. This indemnification, which is uncapped (carved out from the general indemnification cap), provides Meridian with significant protection against third-party infringement claims.
4. Coordination with Patent Prosecution. Penterra should coordinate with Whitford & Cascade Insurance Brokers to ensure that prosecution of pending PPC-4187 applications does not create prosecution history estoppel issues that could affect the FTO position.
VI. Trademark Analysis
A. PENTECLAR Trademark Portfolio
PENTECLAR is the proposed commercial trade name for PPC-4187 (Penteracitinib) in the Licensed Territory and worldwide. Penterra has pursued a global trademark strategy to secure registration of the PENTECLAR mark in all key markets, including all Territory jurisdictions. The following table sets forth the current status of PENTECLAR trademark registrations and applications in relevant jurisdictions.
Table of Trademark Registrations and Applications
All registrations and applications are in International Class 5 (pharmaceutical preparations for the treatment of atopic dermatitis and inflammatory skin conditions). In jurisdictions where the mark has been registered, maintenance filings and renewal deadlines will need to be tracked and managed by the designated trademark counsel.
B. Trademark Clearance Searches
Comprehensive trademark clearance searches were conducted in all Territory jurisdictions prior to filing the PENTECLAR trademark applications. The searches were performed by Bramwell Software (now Marlowe Data Systems) and supplemented by local counsel searches in selected jurisdictions.
Methodology. The clearance searches encompassed: (i) identical mark searches for "PENTECLAR" in Class 5 and related classes; (ii) phonetically similar mark searches, including variations such as "PENTECLAR," "PENTACLAR," "PENTECLAIR," "PENTECLARE," "PENTAKLAR," and similar phonetic equivalents; (iii) common-law trademark searches in jurisdictions where unregistered marks may confer rights; and (iv) domain name searches for penteclar.com and related domain variations. Searches were conducted in pharmaceutical and healthcare classes (Classes 5, 10, 42, and 44) to identify any potential conflicts.
Results. The clearance searches returned no conflicting prior registrations or pending applications for PENTECLAR or phonetically similar marks in any Territory jurisdiction. The closest marks identified were PENTACLOR (a Class 1 industrial chemical trademark registered in Thailand, unrelated to pharmaceutical use) and PENTACARE (a Class 3 cosmetics trademark registered in Indonesia, also unrelated). Neither mark is considered confusingly similar to PENTECLAR in the context of Class 5 pharmaceutical goods, and neither would give rise to a likelihood-of-confusion objection by any Territory trademark office.
Assessment of Potential Confusion with Existing Pharmaceutical Brands. We conducted a supplementary review of existing pharmaceutical brand names to assess whether PENTECLAR could be confused with any marketed pharmaceutical product in the Territory. This review considered phonetic similarity, visual similarity, and therapeutic overlap. No confusingly similar pharmaceutical brands were identified. We note that the JAK inhibitor class includes marketed products under the brand names XELJANZ (tofacitinib, Ashbury Industries), OLUMIANT (baricitinib, Crowne Albany Enterprises), RINVOQ (upadacitinib, Penrose & Co.), and CIBINQO (abrocitinib, Ashbury Industries), none of which is phonetically or visually similar to PENTECLAR.
C. Regulatory Trademark Considerations
INN vs. Trade Name Compliance. The proposed INN "Penteracitinib" and trade name "PENTECLAR" have been reviewed for compliance with WHO INN naming guidelines. The INN uses the stem "-citinib" consistent with the established nomenclature for JAK inhibitors. The trade name PENTECLAR is sufficiently distinct from the INN to avoid confusion between the generic and brand names, satisfying WHO guidelines that require trade names to be clearly distinguishable from INNs.
Japan. The PMDA has specific naming conventions for pharmaceutical products marketed in Japan. Trade names must be reviewed and approved by PMDA as part of the marketing authorization process. We reviewed the PMDA's naming guidelines and assessed the potential for naming objections to PENTECLAR. Based on our analysis, we do not anticipate any PMDA naming objections, as the mark does not incorporate misleading efficacy claims, does not resemble the INN stem in a manner that could cause dispensing errors, and does not conflict with any existing Japanese pharmaceutical product names. Meridian Japan K.K. should confirm PMDA naming requirements with its Japanese regulatory counsel, Yuki Nakamura of Nakamura & Takeda Law Offices, during the marketing authorization application process.
China (PRC). The NMPA requires that pharmaceutical products marketed in China bear Chinese-language trade names. While the English-language PENTECLAR mark has been registered with CNIPA in Class 5, a Chinese-language equivalent trade name will need to be developed and separately cleared for use in the PRC market. The Chinese trade name should be phonetically suggestive of the English-language mark (to maintain brand continuity) while complying with NMPA naming requirements, which prohibit the use of characters that imply exaggerated efficacy, contain superlative language, or could be confused with existing drug names. We recommend that Penterra and Meridian engage a Chinese branding specialist to develop appropriate Chinese-language brand name candidates for clearance searching and registration.
Australia. The TGA's naming requirements for prescription medicines were reviewed, and no issues were identified. The TGA requires that trade names for prescription medicines be distinct from the approved name (INN) and from other registered product names on the Australian Register of Therapeutic Goods. PENTECLAR satisfies these requirements.
D. Trademark Recommendations
Based on our analysis, we make the following recommendations regarding the PENTECLAR trademark portfolio:
1. Proceed with Registrations. Continue prosecution of pending trademark applications in all Territory jurisdictions (Hong Kong SAR, Australia, Thailand, Malaysia, Indonesia, and Vietnam) and maintain registrations in jurisdictions where the mark has been granted.
2. Chinese-Language Trade Name. Develop and file a Chinese-language equivalent trade name for the PRC market as a priority. The selected Chinese name should undergo full clearance searching and should be filed for registration with CNIPA promptly upon selection. This process should be coordinated with Meridian Pharma (Shanghai) Co., Ltd., given Meridian's familiarity with the Chinese pharmaceutical market and regulatory naming requirements.
3. Monitoring. Implement trademark watch services in all Territory jurisdictions to monitor for any third-party filings that could conflict with PENTECLAR or the Chinese-language trade name. This is particularly important in jurisdictions with first-to-file trademark systems, such as China, where bad-faith trademark squatting remains a concern.
4. Trademark License. Under the proposed Transaction, Meridian will be granted an exclusive license to use the PENTECLAR trademark in the Territory pursuant to a separate Trademark License Agreement. This agreement should include provisions for quality control, brand standards, trademark maintenance obligations, and post-termination transition requirements.
VII. Identification of Third-Party IP Risks
A. Third-Party Patent Risks
While the overall FTO analysis concludes that the risk of third-party patent infringement is low, several third-party patents and pending applications have been identified during the diligence process that, while not creating a high infringement risk, warrant ongoing monitoring and, in certain cases, proactive risk management.
Japanese Method-of-Use Patents. As discussed in Section V.C above, three Japanese method-of-use p